PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
about
A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignanciesPalbociclib - from Bench to Bedside and BeyondPalbociclib: First CDK4/6 Inhibitor in Clinical Practice for the Treatment of Advanced HR-Positive Breast CancerCDK4/6 inhibition in luminal breast cancerProfile of palbociclib in the treatment of metastatic breast cancerNovel Molecular Markers for Breast CancerCurrent Medical Treatment of Patients with Non-Colorectal Liver Metastases: Primary Tumor Breast CancerDelaying Chemotherapy in the Treatment of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerCellular Pathways in Response to Ionizing Radiation and Their Targetability for Tumor RadiosensitizationTargeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast CancerTargeting the Checkpoint to Kill Cancer CellsTargeting CDK6 in cancer: State of the art and new insightsNew directions for drug-resistant breast cancer: the CDK4/6 inhibitorsThe other side of the coin: the tumor-suppressive aspect of oncogenes and the oncogenic aspect of tumor-suppressive genes, such as those along the CCND-CDK4/6-RB axisRB1: a prototype tumor suppressor and an enigmaRetinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventionsTherapeutic targeting of replicative immortalityCIViC databasePharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer.Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines.Targeting the RB-E2F pathway in breast cancerTargeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancersApproaches to modernize the combination drug development paradigmAPC/C and retinoblastoma interaction: cross-talk of retinoblastoma protein with the ubiquitin proteasome pathwayAre Estrogen Receptor Genomic Aberrations Predictive of Hormone Therapy Response in Breast Cancer?Palbociclib: A New Option for Front-Line Treatment of Metastatic, Hormone Receptor-Positive, HER2-Negative Breast CancerDevelopmental therapeutics for inflammatory breast cancer: Biology and translational directionsReview of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrantTargeting CDK4 and CDK6: From Discovery to TherapyEnhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling PathwaysBrk/Protein tyrosine kinase 6 phosphorylates p27KIP1, regulating the activity of cyclin D-cyclin-dependent kinase 4Cyclin D as a therapeutic target in cancerFascaplysin as a specific inhibitor for CDK4: insights from molecular modellingThe Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network PerspectiveBGRMI: A method for inferring gene regulatory networks from time-course gene expression data and its application in breast cancer researchDiscovering biological connections between experimental conditions based on common patterns of differential gene expressionTherapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer.High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencingPalbociclib: A breakthrough in breast carcinoma in women.
P2860
Q21245492-C6F52740-32D5-4A46-A1DF-1490825645EBQ26738979-28859B29-EDF3-4426-8198-C3EF20592485Q26738982-3FF5C028-FA2E-4D12-B249-8A61E79E87C0Q26739836-E4C0C156-3A91-42FF-9AC9-C77614C23183Q26747737-3C2CE107-CDDB-464D-A956-D411AB934A0EQ26753160-6DFA7411-EA2A-4866-811A-2B265B12DEE2Q26764987-37464FEB-C5EF-453A-84BE-FB0C6F0DA289Q26770482-C8B6F4D1-7E1F-45EC-A282-3B7156398098Q26771165-66D7C785-0D09-49BE-AF76-24FF844AAD47Q26777734-1D55E54E-B9D0-463D-B3A4-741AAB9FCF66Q26795781-F4BFCA89-EBD7-48AC-B711-0335FCE9DAF0Q26796499-150DD79E-787A-4D0B-A216-AB83792CE5E4Q26797396-66746526-28D8-496B-B78A-88B767A8412BQ26865888-3C40AAE2-A42A-4031-9736-150C754E39DDQ26866393-636CD44F-7639-494F-AED9-696D9840FCACQ27022834-1700840C-3F0F-4615-A15C-2C11EAB159C2Q27027457-1C255D70-358B-4C9E-A515-D9DE6DFAF5C7Q27612411-04E34BB9-5052-48EC-AC78-A9D1B2ED01C5Q27851556-EA2D2253-2025-4193-A72A-B5E13D22B6A4Q27851620-060DB892-B09C-4AE7-9475-2AA18306BC07Q27852814-8DBAFF84-1A7A-4B87-8174-38822BB38F83Q28069626-B47D93FB-C1F9-42B2-A70C-6EFDC958A473Q28069910-A7379C1D-3359-4375-B960-0F0A6CC93F60Q28072074-E7969E66-C3C7-44BC-9053-7700F99E34AEQ28072560-4E4D9F47-BC39-488F-B127-2FC8C6F9E7EFQ28074060-0F3D46DC-8F61-4B25-AD99-F1375DBB812CQ28074156-DCB302B5-0B4D-41F4-9E54-4EDBD9D336E8Q28075322-F19FA492-F29C-4B97-B3C5-C7AD8516D9B4Q28076777-7F58ECA5-79CF-45BF-94A5-7A29B546EE96Q28082912-DE4D47FD-7BA0-489B-AB57-055E62C98EB1Q28084585-65D2431F-7CB3-49C5-B594-EBA422C2A20BQ28115769-C1007329-5B0E-49D1-AC7C-205E375314FAQ28242623-648FD5E4-8947-40D1-894F-B666303E0904Q28482234-B1A99DA4-748C-46EA-8B11-A176BBFE9A72Q28553277-EF5A4437-E0B2-4804-91E9-BF6A42371236Q28595423-79DDFA8F-24EB-4FDB-B8C4-5B3881608215Q28743395-4AD53749-6C56-4977-94F8-7A891832AE3BQ30419997-F09ACCBF-B979-4462-9F8B-E748D1ADB0EEQ30514084-94FF52A0-162A-499C-9FC5-B40507931241Q33438102-D1BF86FB-A062-489A-A7A4-8E8DD1AE81DA
P2860
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
description
2009 nî lūn-bûn
@nan
2009 թուականին հրատարակուած գիտական յօդուած
@hyw
2009 թվականին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
PD 0332991, a selective cyclin ...... ast cancer cell lines in vitro
@ast
PD 0332991, a selective cyclin ...... ast cancer cell lines in vitro
@en
PD 0332991, a selective cyclin ...... ast cancer cell lines in vitro
@en-gb
PD 0332991, a selective cyclin ...... ast cancer cell lines in vitro
@nl
type
label
PD 0332991, a selective cyclin ...... ast cancer cell lines in vitro
@ast
PD 0332991, a selective cyclin ...... ast cancer cell lines in vitro
@en
PD 0332991, a selective cyclin ...... ast cancer cell lines in vitro
@en-gb
PD 0332991, a selective cyclin ...... ast cancer cell lines in vitro
@nl
prefLabel
PD 0332991, a selective cyclin ...... ast cancer cell lines in vitro
@ast
PD 0332991, a selective cyclin ...... ast cancer cell lines in vitro
@en
PD 0332991, a selective cyclin ...... ast cancer cell lines in vitro
@en-gb
PD 0332991, a selective cyclin ...... ast cancer cell lines in vitro
@nl
P2093
P2860
P50
P3181
P356
P1476
PD 0332991, a selective cyclin ...... ast cancer cell lines in vitro
@en
P2093
Amrita J Desai
Camilla Fowst
David J Cohen
Dennis J Slamon
Gerret Los
Mohammad Atefi
Richard S Finn
P2860
P2888
P3181
P356
10.1186/BCR2419
P407
P577
2009-01-01T00:00:00Z
P5875
P6179
1050281960